GAF Healthcare
Specialty Overview

Best Hospitals for Hematopoietic Stem Cell Transplantation (HSCT) in Mumbai, India

17 hematology hospitals in our India network are listed in Mumbai, accredited by JCI, NABH, NABL, ISO 9001, with 6,503 beds combined.

17
Hospitals Listed
1
City
4.6
Avg. Rating
4
Accreditation Types
The Short Answer

This page lists the hematology hospitals in our directory offering Hematopoietic Stem Cell Transplantation (HSCT) in Mumbai, India, including Nanavati Super Specialty Hospital, Kokilaben Dhirubhai Ambani Hospital, Tata Memorial Hospital, Apollo Hospitals, Navi Mumbai and others. Each listing links through to the hospital's full profile page.

Including:🇮🇳 Nanavati Super Specialty Hospital🇮🇳 Kokilaben Dhirubhai Ambani Hospital🇮🇳 Tata Memorial Hospital

Ask us about hematopoietic stem cell transplantation (hsct) in Mumbai, India

Share a few details and our care coordination team will get back to you with next steps.

Top Hospitals for Hematopoietic Stem Cell Transplantation (HSCT) in Mumbai, India

Nanavati Super Specialty Hospital Featured

🇮🇳 Nanavati Super Specialty Hospital

Mumbai, India 5 (12 reviews) 350 beds
Why consider this hospital?
5/5 rating from 12 reviews350 beds
Specialties & Accreditation
OncologyCardiac SurgeryNeurosciencesTransplantBariatrics
JCI — Joint Commission International accreditationNABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by Nanavati Super Specialty Hospital's care team in Mumbai, India, from initial consultation through recovery. Nanavati Super Specialty Hospital, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

5/5
Rating
1950
Established
350
Beds
Mumbai, India
Location
Enquire NowView Profile
Kokilaben Dhirubhai Ambani Hospital

🇮🇳 Kokilaben Dhirubhai Ambani Hospital

Mumbai, India 4.8 (1800 reviews) 750 beds
Why consider this hospital?
4.8/5 rating from 1800 reviews750 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgeryBariatric SurgeryVascular Surgery
JCI — Joint Commission International accreditationNABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by Kokilaben Dhirubhai Ambani Hospital's care team in Mumbai, India, from initial consultation through recovery. Kokilaben Dhirubhai Ambani Hospital, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.8/5
Rating
2009
Established
750
Beds
Mumbai, India
Location
Enquire NowView Profile
Tata Memorial Hospital

🇮🇳 Tata Memorial Hospital

Mumbai, India 4.8 (2500 reviews) 629 beds
Why consider this hospital?
4.8/5 rating from 2500 reviews629 beds
Specialties & Accreditation
OncologyCancer Center
NABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by Tata Memorial Hospital's care team in Mumbai, India, from initial consultation through recovery. Tata Memorial Hospital, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.8/5
Rating
1941
Established
629
Beds
Mumbai, India
Location
Enquire NowView Profile
Apollo Hospitals, Navi Mumbai

🇮🇳 Apollo Hospitals, Navi Mumbai

Mumbai, India 4.8 (512 reviews) 500 beds
Why consider this hospital?
4.8/5 rating from 512 reviews500 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsSpine Surgery
JCI — Joint Commission International accreditationNABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by Apollo Hospitals, Navi Mumbai's care team in Mumbai, India, from initial consultation through recovery. Apollo Hospitals, Navi Mumbai, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.8/5
Rating
2016
Established
500
Beds
Mumbai, India
Location
Enquire NowView Profile
Gleneagles Hospital, Mumbai

🇮🇳 Gleneagles Hospital, Mumbai

Mumbai, India 4.8 (615 reviews) 638 beds
Why consider this hospital?
4.8/5 rating from 615 reviews638 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsGastroenterology
JCI — Joint Commission International accreditationNABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by Gleneagles Hospital, Mumbai's care team in Mumbai, India, from initial consultation through recovery. Gleneagles Hospital, Mumbai, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.8/5
Rating
2008
Established
638
Beds
Mumbai, India
Location
Enquire NowView Profile
Lilavati Hospital And Research Centre

🇮🇳 Lilavati Hospital And Research Centre

Mumbai, India 4.8 (724 reviews) 326 beds
Why consider this hospital?
4.8/5 rating from 724 reviews326 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsGastroenterology
JCI — Joint Commission International accreditationNABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by Lilavati Hospital And Research Centre's care team in Mumbai, India, from initial consultation through recovery. Lilavati Hospital And Research Centre, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.8/5
Rating
1997
Established
326
Beds
Mumbai, India
Location
Enquire NowView Profile
Jaslok Hospital

🇮🇳 Jaslok Hospital

Mumbai, India 4.6 (129 reviews) 350 beds
Why consider this hospital?
4.6/5 rating from 129 reviews350 beds
Specialties & Accreditation
Cardiac SurgeryNeurosciencesOncologyOrthopedicsTransplant
NABH — National Accreditation Board for Hospitals & Healthcare Providers accreditationNABL — National Accreditation Board for Testing and Calibration Laboratories accreditation

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by Jaslok Hospital's care team in Mumbai, India, from initial consultation through recovery. Jaslok Hospital, accredited by NABH, NABL, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.6/5
Rating
1973
Established
350
Beds
Mumbai, India
Location
Enquire NowView Profile
Gleneagles Global Hospitals (Global Hospitals)

🇮🇳 Gleneagles Global Hospitals (Global Hospitals)

Parel, Mumbai, India 4.6 (183 reviews) 450 beds
Why consider this hospital?
4.6/5 rating from 183 reviews450 beds
Specialties & Accreditation
Liver TransplantCardiac SurgeryOrthopedicsOncologyNeurosciences
NABH — National Accreditation Board for Hospitals & Healthcare Providers accreditationJCI — Joint Commission International accreditation

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by Gleneagles Global Hospitals (Global Hospitals)'s care team in Parel, Mumbai, India, from initial consultation through recovery. Gleneagles Global Hospitals (Global Hospitals), accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.6/5
Rating
1996
Established
450
Beds
Parel, Mumbai, India
Location
Enquire NowView Profile
Medicover Hospital, Navi Mumbai

🇮🇳 Medicover Hospital, Navi Mumbai

Navi Mumbai, India 4.6 (143 reviews) 310 beds
Why consider this hospital?
4.6/5 rating from 143 reviews310 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyOrthopedicsNeurologyGastroenterology
NABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by Medicover Hospital, Navi Mumbai's care team in Navi Mumbai, India, from initial consultation through recovery. Medicover Hospital, Navi Mumbai, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.6/5
Rating
2023
Established
310
Beds
Navi Mumbai, India
Location
Enquire NowView Profile
KIMS Hospitals, Thane

🇮🇳 KIMS Hospitals, Thane

Mumbai, India 4.6 (58 reviews) 300 beds
Why consider this hospital?
4.6/5 rating from 58 reviews300 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsSpine Surgery
NABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation

Patients considering hematopoietic stem cell transplantation (hsct) can be cared for by KIMS Hospitals, Thane's care team in Mumbai, India, from initial consultation through recovery. KIMS Hospitals, Thane, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing hematopoietic stem cell transplantation (hsct).

4.6/5
Rating
2025
Established
300
Beds
Mumbai, India
Location
Enquire NowView Profile

Top Hematology Doctors in Mumbai, India

Image not available Featured

Dr. Muralidaran C

MBBS, MD, DM (Clinical Hematology)
Consultant Hematologist & Bone Marrow Transplant Physician · Specialty: Hematologist & BMT Specialist
Wockhardt Hospital Mumbai, India9+ Years experience
Why consider this doctor?
  • 9+ years of experience in Hematologist & BMT Specialist
  • Consultant Hematologist & Bone Marrow Transplant Physician, Wockhardt Hospital, Mumbai — Present
  • Superspecialty Medical Officer, MCGM–CTC PHO BMT Centre, Mumbai
Expertise & Procedures
  • Bone Marrow Aspiration and Biopsy
  • Autologous Stem Cell Transplantation (ASCT)
  • Allogeneic Bone Marrow Transplantation
  • Haploidentical BMT with Haploidentical Donors
  • Lymph Node Fine Needle Aspiration Cytology (FNAC)
View all procedures →
Hematologist & BMT Specialist Experience: 9+ YearsHospital Affiliation: Wockhardt HospitalHospital accreditation: NABH, NABL
View Profile Book a Consultation
Image not available

Dr. Vipin Khandelwal

MBBS, MD (Paediatrics), DM (Paediatric Oncology), PDF (Paediatric Haematology & BMT)
Consultant — Paediatric Haematology, Oncology & Bone Marrow Transplantation · Specialty: Paediatric Haematologist & BMT Specialist
Apollo Hospitals Navi Mumbai, India12+ Years experience
Why consider this doctor?
  • 12+ years of experience in Paediatric Haematologist & BMT Specialist
  • Consultant — Paediatric Haematology, Oncology & Bone Marrow Transplantation, Apollo Hospitals, Navi Mumbai
  • Advanced training in Paediatric Haematology and Bone Marrow Transplantation
Expertise & Procedures
  • Paediatric Bone Marrow Transplantation (BMT)
  • Haploidentical Stem Cell Transplantation
  • Matched Sibling Donor Transplant
  • Matched Unrelated Donor Transplant
  • Autologous Stem Cell Transplantation
View all procedures →
Paediatric Haematologist & BMT Specialist Experience: 12+ YearsHospital Affiliation: Apollo HospitalsHospital accreditation: JCI, NABH
View Profile Book a Consultation
Our Methodology

How we selected these hospitals

A hospital appears on this page when Hematology is among its listed specialties and it is located in Mumbai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.

What To Look For

How to Select the Best Hospital for Hematopoietic Stem Cell Transplantation (HSCT) in Mumbai, India?

Choosing the right hospital for hematopoietic stem cell transplantation (hsct) is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:

International Accreditation

Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.

Specialization

Check that the hospital's listed specialties actually include hematology rather than only general care.

Capacity and Track Record

Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.

Transparent Costs

Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.

Clinical Overview

Understanding Hematopoietic Stem Cell Transplantation (HSCT)

Haematopoietic Stem Cell Transplantation (HSCT), commonly known as Bone Marrow Transplantation (BMT), is a life-saving procedure used to reconstitute a patient's haematopoietic system following high-dose chemotherapy or radiation, with allogeneic HSCT achieving long-term disease-free survival rates of 50–80% depending on disease type, donor compatibility, and patient fitness.

30–60 days (inpatient; varies by transplant type — autologous typically 21–35 days, allogeneic 40–60 days)
Hospital Stay
10–16 weeks from transplant day (fit-to-fly clearance requires stable engraftment, absence of active GVHD, ANC ≥ 0.5 × 10⁹/L sustained, and infectious disease clearance by the treating haematologist)
Total Stay in Country (Fit-to-Fly)
50–80% long-term disease-free survival (disease- and donor-dependent; autologous HSCT for multiple myeloma: 70–85%; matched sibling allogeneic HSCT for AML in CR1: 55–70%)
Success Rate

Clinical Overview

  • Haematopoietic Stem Cell Transplantation (HSCT) is the infusion of pluripotent haematopoietic progenitor cells — sourced from bone marrow, peripheral blood, or umbilical cord blood — into a conditioned recipient with the goal of restoring normal haematopoiesis and, in allogeneic settings, inducing a graft-versus-tumour (GVT) immune effect.
  • The procedure is broadly classified as autologous (patient's own stem cells re-infused after myeloablative chemotherapy) or allogeneic (donor cells from a matched sibling, matched unrelated donor, haploidentical relative, or cord blood unit).
  • The physiological impact is profound: conditioning regimens such as BuCy (busulfan + cyclophosphamide), FluBu (fludarabine + busulfan), or TBI-based protocols ablate the recipient's marrow, rendering them profoundly immunosuppressed and pancytopenic for 2–6 weeks before donor engraftment restores marrow function.
Full details →

Who is a Candidate?

  • ELIGIBLE CONDITIONS (Malignant): Acute Myeloid Leukaemia (AML) in CR1/CR2, Acute Lymphoblastic Leukaemia (ALL) in CR1 (high-risk) or CR2, Chronic Myeloid Leukaemia (CML) in accelerated/blast phase or TKI-refractory, Myelodysplastic Syndromes (MDS) with IPSS-R intermediate or higher, Hodgkin and Non-Hodgkin Lymphoma (relapsed/refractory or high-risk), Multiple Myeloma (autologous HSCT as consolidation post-induction), Myelofibrosis (allogeneic HSCT for DIPSS+ intermediate-2 or high risk)
  • ELIGIBLE CONDITIONS (Non-Malignant): Severe Aplastic Anaemia (SAA), Thalassaemia Major (Lucarelli Class I–III), Sickle Cell Disease with major organ complications, SCID and primary immunodeficiencies, Fanconi Anaemia, Wiskott-Aldrich Syndrome, Hurler Syndrome and selected lysosomal storage disorders, POEMS syndrome
  • ELIGIBLE CONDITIONS (Autoimmune — Investigational/Specialist Centres): Refractory Multiple Sclerosis (MS), Systemic Sclerosis, Crohn's Disease (autologous HSCT under EBMT guidelines)
  • REQUIRED PRE-TRANSPLANT DIAGNOSTICS: Bone marrow biopsy and trephine with cytogenetics (karyotype, FISH), molecular profiling (NGS panel for FLT3, NPM1, IDH1/2, TP53, ASXL1), HLA typing (high-resolution 10/10 allele-level for patient and donor), PET-CT scan (for lymphoma patients to confirm complete remission pre-transplant), ECHO (left ventricular ejection fraction must typically be ≥ 45%), Pulmonary Function Tests (DLCO ≥ 50% predicted), Creatinine clearance (GFR ≥ 40–60 mL/min depending on regimen), Liver function and bilirubin (Child-Pugh scoring), CMV/EBV/HSV/VZV/HBV/HCV/HIV serology for patient and donor, HCT-CI comorbidity scoring, Dental clearance and ENT evaluation, Fertility counselling and sperm/oocyte cryopreservation discussion
  • +1 more

Treatment Options & Approaches

  • AUTOLOGOUS HSCT (Auto-SCT):

Recovery

  • PHASE 1 — INITIAL ASSESSMENT & GAF HEALTHCARE CASE REVIEW (Weeks -12 to -8 before transplant):

Risks to be aware of

  • HSCT carries significant treatment-related morbidity and mortality that every patient and family must understand prior to proceeding.
  • The overall treatment-related mortality (TRM) at 100 days ranges from 2–5% for autologous HSCT in fit patients to 10–25% for myeloablative allogeneic HSCT in high-risk or older patients, largely driven by infection, organ toxicity, and GVHD.
Full details →

Why GAF Healthcare

  • GAF Healthcare provides comprehensive end-to-end non-medical support for international HSCT patients and their attendants, ensuring that logistical complexity never becomes a barrier to accessing life-saving treatment.

Common questions about Hematopoietic Stem Cell Transplantation (HSCT)

What is the cost of Haematopoietic Stem Cell Transplantation (HSCT) / Bone Marrow Transplantation in India versus the UAE?
The total in-hospital cost of HSCT varies significantly based on the transplant type (autologous vs. allogeneic), donor source (matched sibling, matched unrelated, or haploidentical), conditioning regimen intensity, length of inpatient stay, and any complications requiring additional intervention. In India, autologous HSCT (e.g., for multiple myeloma or lymphoma) typically costs between USD 18,000 and USD 28,000 inclusive of conditioning chemotherapy, stem cell collection and cryopreservation, the transplant admission (21–35 days), supportive medications, blood products, and standard monitoring. Allogeneic HSCT — matched sibling, MUD, or haploidentical — costs between USD 28,000 and USD 45,000, with higher costs driven by longer inpatient stays (40–60 days), GVHD prophylaxis drugs (tacrolimus, sirolimus, ATG), and intensive infection surveillance. These costs reflect care at NABH- and JCI-accredited centres in cities such as Mumbai, Delhi, Bengaluru, Chennai, and Hyderabad, which collectively perform among the highest volumes of HSCT in Asia. In the UAE (Dubai and Abu Dhabi), the same procedures are priced at USD 45,000–65,000 for autologous HSCT and USD 70,000–110,000 for allogeneic HSCT. UAE centres offer premium single-room accommodation, internationally trained nursing staff with lower nurse-to-patient ratios, and luxury patient services, along with JCI accreditation and DHA/DOH regulatory oversight. These costs are still 60–75% below equivalent procedures in the United States (where allo-HSCT routinely exceeds USD 300,000–500,000) or the United Kingdom. Neither range includes international matched unrelated donor (MUD) search and procurement fees (typically USD 5,000–20,000 depending on the registry and urgency), pre-transplant diagnostics conducted abroad, post-discharge outpatient medications, or return flights and accommodation. GAF Healthcare provides a fully itemised, personalised cost estimate within 5–7 business days of receiving complete medical records.
How long do I need to stay in India or the UAE before I am fit to fly home after HSCT?
HSCT requires one of the longest mandatory in-country stays of any medical procedure, and patients and families must plan accordingly. The minimum in-country duration before fit-to-fly clearance is 10–16 weeks from the day of stem cell infusion (Day 0), though the median for allogeneic HSCT patients is 12–14 weeks. The hospital inpatient admission itself lasts 21–35 days for autologous HSCT and 40–60 days for allogeneic HSCT (longer if complications such as GVHD, CMV reactivation, or prolonged engraftment occur). Following discharge from the inpatient unit, patients are not fit to fly and must remain near the transplant centre for outpatient monitoring. During this phase, patients are seen 3–5 times per week (reducing to weekly as recovery progresses) for blood counts, drug level monitoring, GVHD assessment, and infectious surveillance. Formal fit-to-fly clearance is issued by the transplant physician when ALL of the following criteria are met: - Absolute Neutrophil Count (ANC) sustainably above 1.0 × 10⁹/L without G-CSF support - Platelet count ≥ 50 × 10⁹/L (or ≥ 80 × 10⁹/L for long-haul flights > 8 hours, at many centres) - No active GVHD Grade II or above requiring escalation of therapy - No active systemic infection (bacterial, fungal, or viral) - Stable oral immunosuppression with documented therapeutic drug levels - ECOG Performance Status ≤ 2 (patient can perform basic self-care and ambulate) - No supplemental oxygen requirement For allogeneic HSCT patients, fit-to-fly is rarely achievable before Week 10 post-transplant, and the majority are cleared between Weeks 12 and 16. Autologous HSCT patients may occasionally achieve fit-to-fly clearance as early as Week 6–8, but Week 8–12 is more typical. These timelines can be extended by complications. GAF Healthcare's Case Manager works with the transplant team to coordinate fit-to-fly certification, arrange medical escort if required, and liaise with airlines regarding oxygen requirements, preboarding, and infection precautions during travel.
What is the success rate of HSCT / Bone Marrow Transplantation?
The success rate of HSCT is not a single number — it is disease-specific, risk-stratified, and dependent on multiple patient, disease, and transplant-related factors. Published outcomes from EBMT (European Bone Marrow Transplantation Registry), CIBMTR (Center for International Blood and Marrow Transplant Research), and individual high-volume centres provide the most reliable benchmark data. KEY OUTCOME BENCHMARKS BY DISEASE AND TRANSPLANT TYPE: - Autologous HSCT for Multiple Myeloma (MM): 5-year progression-free survival (PFS) of 40–55% with modern induction (VRd or Dara-VRd) plus autologous transplant and lenalidomide maintenance; overall survival (OS) exceeds 70–80% at 5 years with tandem auto approach in high-risk disease. - Autologous HSCT for Hodgkin Lymphoma (relapsed/refractory, chemosensitive): 5-year OS of 50–60%; when combined with brentuximab vedotin consolidation post-transplant, 5-year PFS improves to approximately 65%. - Allogeneic HSCT for AML in First Complete Remission (CR1), standard-risk: 5-year disease-free survival (DFS) of 55–70% with matched sibling donor; 50–65% with MUD; approximately 45–60% with haploidentical (PTCy protocol). - Allogeneic HSCT for ALL in CR1 (high-risk, Ph+ or MRD-positive): 5-year DFS of 50–65% with MSD; outcomes are strongly influenced by MRD negativity at transplant. - Allogeneic HSCT for Severe Aplastic Anaemia (SAA) with MSD in patients < 40 years: 5-year OS exceeding 85–90%, making it potentially curative in the majority. - Allogeneic HSCT for Thalassaemia Major (Lucarelli Class I): event-free survival (EFS) of 85–93% in paediatric patients with MSD and good pre-transplant hepatic status. - Allogeneic HSCT for MDS (IPSS-R High/Very High): 3-year OS of 35–50%, heavily dependent on cytogenetic risk and MRD status at transplant. CRITICAL PROGNOSTIC FACTORS: The Disease Risk Index (DRI) — low, intermediate, high, and very high — is the most validated risk stratification tool and correlates strongly with post-HSCT survival. Low-DRI patients achieve 3-year OS > 65%; very-high-DRI patients < 30%. The HCT-CI (Haematopoietic Cell Transplantation Comorbidity Index) predicts treatment-related mortality independent of disease. KPS/ECOG performance status, CMV serostatus, MRD negativity at transplant, and donor-recipient sex mismatch also independently influence outcomes. GAF Healthcare's partner centres in India and the UAE report outcomes that are broadly consistent with published EBMT and CIBMTR registry data, reflecting their volume, experience, and protocol adherence. During the case review process, GAF Healthcare will share the transplant centre's disease-specific outcome data and help patients and families interpret the individualised risk-benefit assessment provided by the treating haematologist.

Related pages

How GAF Healthcare Assists in Choosing the Best Hospital for Hematopoietic Stem Cell Transplantation (HSCT) in Mumbai, India

Discover the Top Hospitals for Hematopoietic Stem Cell Transplantation (HSCT) in Mumbai, India

This page lists 17 accredited hematology hospitals in Mumbai, India, so you can compare accreditation, specialties and bed capacity in one place.

Support When You Need It Most

Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.

Transparent, All-Inclusive Costs

We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.

Visa, Travel and Stay Coordination

Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.

Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.

Patient Success Story

Iraqi Family's Journey: Baby Ibrahim's Life-Saving Heart Surgery in India
Common Questions

Frequently asked questions about hematopoietic stem cell transplantation (hsct) in Mumbai, India

How many hematology hospitals are listed in Mumbai, India?
17 hospitals in our Mumbai, India directory are currently listed for hematology including Hematopoietic Stem Cell Transplantation (HSCT).
How do you choose which hospitals to list?
A hospital appears on this page when Hematology is among its listed specialties and it is located in Mumbai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How much does treatment cost in India?
Cost varies by hospital, city and individual case. Use our cost calculator for a personalized estimate — see the link on this page.
Are there hematology hospitals for this in other India cities?
See the "Hospitals in other cities" links on this page for the full India list.
Are these hospitals internationally accredited?
Hospitals listed on this page carry accreditations including JCI, NABH, NABL, ISO 9001 — see the accreditation badge shown for each hospital below.
Can I get a treatment plan and cost estimate before I travel?
Yes. Share your medical reports with the GAF Healthcare team over WhatsApp or email, and our medical team will review them and come back with a recommended hospital, a treatment plan and an itemised cost estimate before you commit to anything.
Do you help with visa, travel and accommodation?
Yes. Once you choose a hospital, our team helps arrange the medical visa invitation letter, book accommodation near the hospital, and organise airport pickup and transport to appointments.
What support do I get during and after treatment?
Our medical team reviews your reports and stays in touch throughout your treatment journey — from the first consultation through recovery, including after you return home.
What does the "Featured" label next to a hospital's name mean?
"Featured" reflects editorial prominence on this listing, not a clinical ranking or a claim that it is the "best" hospital.
How do I get matched with the right hospital for hematopoietic stem cell transplantation (hsct)?
Share your medical reports and requirements with the GAF Healthcare team, and our medical coordinators will recommend a suitable hospital from this list based on your case.
Does the listed cost cover everything?
The figures shown are an indicative planning estimate, not a final quote from a specific hospital. Our team provides a single, itemised, all-inclusive quote before you make any commitment.
🤔

Still have questions?

Our coordinators are here to answer your questions about hematopoietic stem cell transplantation (hsct) in Mumbai, India.

Next Step

Share your medical reports with us and our team will recommend a hospital and treatment plan for hematopoietic stem cell transplantation (hsct) in Mumbai, India.

Contact us to report an inaccuracy on this page.

WhatsApp Us